Results 201 to 210 of about 344,219 (352)

Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster   +68 more
wiley   +1 more source

Esophageal myotomy and risk of esophageal cancer and mortality in achalasia: Real-world cohort study. [PDF]

open access: yesEndosc Int Open
Jaber F   +8 more
europepmc   +1 more source

Stratigraphies: The Long Poem of Place

open access: yes, 2018
This article examines the contemporary long poem of place, beginning with the author's own work 'The Hill' and exploring what drives contemporary poets to work in long form when writing about place.
openaire  

Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This review assessed 52 biomarkers predicting systemic therapy response and adverse events in atopic dermatitis. Most studies focused on dupilumab, and findings were inconsistent. IgE and eosinophils were largely non‐predictive, though elevated eosinophils and LDH sometimes indicated poorer outcomes.
Eva Hilger   +11 more
wiley   +1 more source

Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in Japan [PDF]

open access: hybrid, 2018
Chika Kawajiri‐Manako   +17 more
openalex   +1 more source

Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
JADE EXTEND is an ongoing phase 3, long‐term extension study of previous abrocitinib trials. Patients were adults and adolescents ≥12 years with moderate‐to‐severe atopic dermatitis. Long‐term abrocitinib treatment resulted in clinically meaningful outcomes and improvements in patient‐reported outcomes up to Week 112 in patients with moderate‐to‐severe
Melinda J. Gooderham   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy